ARTICLE SUMMARY:
Financings were meager but steady in H1 2025 despite risk-averse investors looking for later-stage, safe deals; Expectations for medtech M&A in H2 2025; Sequel Med Tech launches its new automated insulin delivery system; the Women’s Brain Foundation focuses on sex- and gender-specific precision therapies; Real-world evidence illuminates trends in TAVR and SAVR utilization; leveraging public relations to reach your company's goals; Profiles of envVino, Fasiki, LumaVision, and ShiraTronics.
